- Linsitinib is the first and only oral small molecule therapy to establish statistical and clinical significance in Thyroid Eye Disease (TED) - Phase 2b/3 LIDS trial met primary endpoint of proptosis ...
- Linsitinib was well-tolerated particularly in IGF-1R areas of interest such as hearing impairment, glycemic changes, and menstrual cycle changes - Confirmatory Phase 3 trial on track to commence in ...
ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ -- Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye ...
ANN ARBOR, Mich., Jan. 14, 2025 /PRNewswire/ -- Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback